Literature DB >> 26095179

Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.

Kalyan Ram Bhamidimarri, Bhamidimarri Kalyan Ram1, Frank Czul, Czul Frank2, Adam Peyton, Peyton Adam1, Cynthia Levy, Levy Cynthia1, Maria Hernandez, Hernandez Maria1, Lennox Jeffers, Jeffers Lennox1, David Roth, Roth David3, Eugene Schiff, Schiff Eugene1, Christopher O'Brien, O'Brien Christopher1, Paul Martin1, Martin Paul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26095179     DOI： 10.1016/j.jhep.2015.06.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  32 in total

1.  Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.

Authors:  Kalyan Ram Bhamidimarri
Journal:  Ann Transl Med       Date:  2016-10

2.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

3.  Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Authors:  Varun Saxena; Farrukh M Koraishy; Meghan E Sise; Joseph K Lim; Monica Schmidt; Raymond T Chung; Annmarie Liapakis; David R Nelson; Michael W Fried; Norah A Terrault
Journal:  Liver Int       Date:  2016-03-24       Impact factor: 5.828

Review 4.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.

Authors:  Pankaj Puri; Vivek A Saraswat; Radha K Dhiman; Anil C Anand; Subrat K Acharya; Shivaram P Singh; Yogesh K Chawla; Deepak N Amarapurkar; Ajay Kumar; Anil Arora; Vinod K Dixit; Abraham Koshy; Ajit Sood; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Anshu Srivastava; Ashish Kumar; Manav Wadhawan; Amit Goel; Abhai Verma; Gaurav Pandey; Rohan Malik; Swastik Agrawal
Journal:  J Clin Exp Hepatol       Date:  2016-07-02

Review 5.  Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends.

Authors:  Sailaja Kesiraju; Praneeth Srikanti; S Sahariah
Journal:  Virusdisease       Date:  2017-08-24

Review 6.  Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.

Authors:  Sarah Talavera Pons; Anne Boyer; Geraldine Lamblin; Philip Chennell; François-Thibault Châtenet; Carine Nicolas; Valérie Sautou; Armand Abergel
Journal:  Br J Clin Pharmacol       Date:  2016-10-26       Impact factor: 4.335

7.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

Review 8.  Hepatitis C Virus Infection in Chronic Kidney Disease.

Authors:  Marco Ladino; Fernando Pedraza; David Roth
Journal:  J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 10.121

9.  Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.

Authors:  Jessica L Michal; Saira Rab; Manish Patel; Alison W Kyle; Lesley S Miller; Kirk A Easley; Aley G Kalapila
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-19       Impact factor: 2.205

10.  Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.

Authors:  Sunil Taneja; Ajay Duseja; Arka De; Manu Mehta; Raja Ramachandran; Vivek Kumar; Harbir Singh Kohli; Krishan Lal Gupta; Radha Krishan Dhiman; Yogesh Chawla
Journal:  Dig Dis Sci       Date:  2018-02-26       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.